Skip to main content
MedinCell receives a new grant to develop a best-in-class long-acting injectable product for HIV PrEP
September 4, 2019
MedinCell partners to address the untapped financial potential in Animal Health
August 28, 2019
Long-acting injectable antipsychotic using MedinCell’s technology receives FDA IND clearance to initiate clinical activities
August 26, 2019
Publication of the 2018/2019 Annual Financial Report
July 31, 2019
Third long-acting injectable antipsychotic using MedinCell’s technology enters preclinical development
July 9, 2019
MedinCell receives 7,5 M€ from the European Bank of Investment (EIB)
July 7, 2019
MedinCell announces 2018/19 fiscal year results
June 4, 2019
Shareholders audioconference and publication of the results for the 2018-2019 financial year, on June 4, 2019
May 22, 2019
MedinCell demonstrates in vivo the efficacy of the first injectable combining surgical anesthesia and 3 days opioid free postoperative pain management
March 11, 2019
MedinCell receives funding for the second formulation phase of its 6-month injectable contraceptive
January 24, 2019
